Back to top
more

Emergent Biosolutions (EBS)

(Delayed Data from NYSE)

$9.35 USD

9.35
1,634,358

+0.41 (4.59%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $9.23 -0.12 (-1.28%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Axsome's NDA Filing for Migraine Candidate in Q4 on Track

by Zacks Equity Research

Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-07, which is developed as an acute treatment of migraine. The company is on course to file the NDA in Q4.

Sorrento to Buy Privately-Held SmartPharm to Boost Pipeline

by Zacks Equity Research

Sorrento (SRNE) signs agreement to acquire SmartPharm Therapeutics in exchange for its common stock worth up to $19.4 million.

BioMarin (BMRN) Files NDA for Vosoritide to Treat Dwarfism

by Zacks Equity Research

BioMarin's (BMRN) BLA for vosoritide is based on final data from a phase III study, long-term data from the ongoing phase II and phase III extension studies and extensive natural history data.

Pluristem Completes Enrollment in Phase I Hematology Study

by Zacks Equity Research

Pluristem (PSTI) completes enrollment in the phase I study in patients with complete hematopoietic recovery following hematopoietic cell transplantation in the United States and Israel.

Alkermes Starts Phase II Study on ALKS 4230 for Solid Tumors

by Zacks Equity Research

Alkermes (ALKS) initiates phase II ARTISTRY-3 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy in patients with advanced solid tumors.

MannKind (MNKD) in Focus: Stock Moves 8.7% Higher

by Zacks Equity Research

MannKind (MNKD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

CRISPR Therapeutics (CRSP) Surges: Stock Moves 6% Higher

by Zacks Equity Research

CRISPR Therapeutics (CRSP) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Albireo Down on Unimpressive Data From Mid-Stage NASH Study

by Zacks Equity Research

Albireo (ALBO) discontinues development of elobixibat in fatty liver diseases, following failure to achieve proof-of-concept for key NASH measures except LDL-C levels in a phase II study.

FDA Nods to Emergent's (EBS) Narcan Shelf Life Extension

by Zacks Equity Research

Emergent's (EBS) Narcan nasal spray gets an FDA nod to extend its shelf life from two years to three years.

Unity Shares Slump 66% As Lead Arthritis Drug Fails in Study

by Zacks Equity Research

Unity's (UBX) lead pipeline candidate, UBX0101, fails to meet primary endpoint in a phase II study in patients with moderate-to-severe painful osteoarthritis of the knee.

Has Emergent Biosolutions (EBS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (EBS) Outperforming Other Medical Stocks This Year?

Novavax (NVAX) to Supply Coronavirus Vaccine to UK Government

by Zacks Equity Research

Novavax (NVAX) enters an agreement to provide the UK government with 60 million doses of its COVID-19 vaccine, NVX-CoV2373, if approved.

BioMarin's MAA for Dwarfism Candidate Gets EMA Validation

by Zacks Equity Research

The EMA sanctions BioMarin's (BMRN) marketing authorization application for vosoritide to treat children with achondroplasia, the most common type of dwarfism.

Novo Nordisk (NVO) Resumes Phase III Hemophilia Studies

by Zacks Equity Research

Novo Nordisk (NVO) resumes the phase III studies on concizumabin in hemophilia A and B patients regardless of inhibitor status.

Ascendis' Dwarfism Candidate Gets Orphan Drug Status in EU

by Zacks Equity Research

Ascendis' (ASND) TransCon CNP receives an Orphan Drug tag in Europe for the treatment of achondroplasia, the most common type of dwarfism.

Roche's Xolair sBLA for Self Administration Accepted by FDA

by Zacks Equity Research

The FDA accepts Roche's (RHHBY) sBLA for a new self-administration option for Xolair across all approved U.S. indications.

Axsome's (AXSM) Earnings Beat in Q2, Pipeline Progresses

by Zacks Equity Research

Axsome (AXSM) incurs a narrower loss in the second quarter of 2020. The company remains on track to submit the NDA for AXS-05 and AXS-07.

Novavax's (NVAX) Earnings Beat in Q2, Sales Lag Estimates

by Zacks Equity Research

Novavax's (NVAX) loss narrows for the second quarter of 2020 but revenues miss the mark.

Reata (RETA) Q2 Earnings Top, Omaveloxolone Setback Hurts

by Zacks Equity Research

Reata (RETA) gets FDA recommendation to initiate a second study on omaveloxolone for additional data.

Esperion (ESPR) Q2 Earnings Top, Drug Sales Hurt by Coronavirus

by Zacks Equity Research

Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings and misses for sales.

AVEO Pharmaceuticals' (AVEO) Q2 Earnings Surpass Estimates

by Zacks Equity Research

AVEO (AVEO) reports a narrower-than-expected loss but misses sales estimates in the second quarter of 2020.

Biohaven (BHVN) Q2 Earnings Beat on Strong Nurtec Uptake

by Zacks Equity Research

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, demonstrates strong launch uptake.

Editas' (EDIT) Earnings Beat in Q2, Revenues Improve Y/Y

by Zacks Equity Research

Editas' (EDIT) both bottom and the top line better estimates for the second quarter of 2020.

Iovance (IOVA) Q2 Earnings Beat Estimates, Pipeline in Focus

by Zacks Equity Research

Iovance's (IOVA) second-quarter bottom line beats estimates. The company is progressing well with its lead pipeline candidates.

Amicus' (FOLD) Q2 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Amicus (FOLD) posts a narrower-than-expected loss, while sales beat estimates in the second quarter of 2020.